| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
Biologicals (Pharmacology)TNF alpha| 1 | 2009 | Infectious complications associated with monoclonal antibodies and related small molecules. | 
| + | - | nl | Clin Microbiol Rev 22(2):274-90, Table of Contents (2009) |
| 2 | 2009 | Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. |
| + | - | nl | Emerg Infect Dis 15(10):1556-61 (2009) |
| 3 | 2009 | Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe. |
| + | - | nl | Emerg Infect Dis 15(6):956-9 (2009) |
| 4 | 2006 | Adverse side-effects to biological agents. |
| + | - | nl | Allergy 61(8):912-20 (2006) |
| 5 | 2006 | A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents. |
| + | - | nl | Ann Rheum Dis 65(12):1541-4 (2006) |
| 6 | 2008 | Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. |
| + | - | nl | Aliment Pharmacol Ther 27(1):19-30 (2008) |
| 7 | 2003 | Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. |
| + | - | nl | Aliment Pharmacol Ther 17(1):75-84 (2003) |
| 8 | 2009 | Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. |
| + | - | nl | Aliment Pharmacol Ther 29(9):921-7 (2009) |
| 9 | 2008 | The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. |
| + | - | nl | Aliment Pharmacol Ther 28(2):221-7 (2008) |
| 10 | 2009 | Skin toxicities associated with epidermal growth factor receptor inhibitors. |
| + | - | nl | Target Oncol 4(2):107-19 (2009) |
| 11 | 2009 | Renal toxicity of targeted therapies. |
| + | - | nl | Target Oncol 4(2):121-33 (2009) |
| 12 | 2009 | Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. |
| + | - | nl | Target Oncol 4(2):99-105 (2009) |
| 13 | 2009 | Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. |
| + | - | nl | Target Oncol 4(2):67-76 (2009) |
| 14 | 2008 | Hematopoietic growth factors: ESMO recommendations for the applications. |
| + | - | nl | Ann Oncol 19 Suppl 2(-):ii116-8 (2008) |
| 15 | 2007 | The clinical use of antibodies in haematological malignancies. |
| + | - | nl | Ann Oncol 18 Suppl 9(-):ix51-7 (2007) |
| 16 | 2005 | Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. |
| + | - | nl | Ann Oncol 16(9):1425-33 (2005) |
| 17 | 2007 | Mechanisms of adverse effects of anti-VEGF therapy for cancer. |
| + | - | nl | Br J Cancer 96(12):1788-95 (2007) |
| 18 | 2007 | Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. |
| + | - | nl | Cancer 109(11):2182-9 (2007) |
| 19 | 2003 | Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs? |
| + | - | nl | Clin Cancer Res 9(4):1231-2 (2003) |
| 20 | 2008 | Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. |
| + | - | nl | Oncologist 13(9):1001-11 (2008) |
| 21 | 2008 | Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. |
| + | - | nl | Oncologist 13(6):725-32 (2008) |
| 22 | 2007 | Review: side effects of approved molecular targeted therapies in solid cancers. |
| + | - | nl | Oncologist 12(12):1443-55 (2007) |
| 23 | 2007 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. |
| + | - | nl | Ann Rheum Dis 66 Suppl 3(-):iii2-22 (2007) |
| 24 | 2005 | Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. |
| + | - | nl | Ann Rheum Dis 64 Suppl 4(-):iv2-14 (2005) |
| 25 | 2011 | Promising new treatments for rheumatoid arthritis - the kinase inhibitors. |
| + | - | nl | Bull NYU Hosp Jt Dis 69(3):233-7 (2011) |
| 26 | 2009 | Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. |
| + | - | nl | Mayo Clin Proc 84(11):979-84 (2009) |
| 27 | 2008 | Development of sarcoidosis during etanercept therapy. |
| + | - | nl | Intern Med 47(11):1021-5 (2008) |
| 28 | 2011 | Cutaneous side-effects of EGFR inhibitors and their management. |
| + | - | nl | Skin Therapy Lett 16(1):1-3 (2011) |
| 29 | 2007 | Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. |
| + | - | nl | Skin Therapy Lett 12(6):1-5 (2007) |
| 30 | 2010 | How tumour necrosis factor blockers interfere with tuberculosis immunity. |
| + | - | nl | Clin Exp Immunol 161(1):1-9 (2010) |
